Tolerability of continuous subcutaneous octreotide used in combination with other drugs.
Continuous subcutaneous infusion of octreotide combined with other drugs has proved to be useful in some circumstances in palliative care setting when theoral route is no longer available. Forty-four patients were administered octreotide alone or in combination with other drugs in the same syringe driver for symptom control in advanced cancer patients. Good tolerability and compatibility were observed without visual drug precipitation for a period of 48 hours at room temperature, the standard clinical situation in patients' homes. Such a combination of drugs administered by the subcutaneous route makes possible the adequate control of symptoms in the final days of life.
Mercadante
S
S
Pain Relief and Palliative Care Unit, SAMOT, Palermo, Italy.
D000328:Adult; D004338:Drug Combinations; D004355:Drug Stability; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D007260:Infusion Pumps; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D010148:Intractable Pain / Q000188:drug therapy*; D010166:Palliative Care / Q000379:methods*
D004338:Drug Combinations; D005765:Gastrointestinal Agents; D015282:Octreotide